ESR1 and breast cancer: Initial results of the ER pathway model provide evidence that the ER pathway is not always active in breast cancer tissue from patients in which routine ER evaluation indicates ER positivity, and also that ER pathway activity as identified by the model is associated with improved clinical outcome after adjuvant hormonal treatment [2].